Gilead Sciences (NASDAQ:GILD) Trading Up 0.3%

Gilead Sciences, Inc. (NASDAQ:GILD) shot up 0.3% during trading on Friday . The stock traded as high as $70.66 and last traded at $70.18. 717,956 shares were traded during mid-day trading, a decline of 90% from the average session volume of 7,465,747 shares. The stock had previously closed at $69.97.

Analysts Set New Price Targets

Several research firms recently commented on GILD. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Friday, April 26th. Royal Bank of Canada reiterated a “sector perform” rating and set a $74.00 price objective on shares of Gilead Sciences in a research note on Monday, July 1st. Maxim Group dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. UBS Group decreased their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, TD Cowen decreased their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a report on Friday, April 26th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has an average rating of “Hold” and an average target price of $84.00.

Gilead Sciences Trading Up 0.6 %

The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The firm’s 50-day simple moving average is $66.32 and its 200 day simple moving average is $71.87. The stock has a market capitalization of $87.70 billion, a P/E ratio of 194.94, a PEG ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion for the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.37 EPS. Equities research analysts anticipate that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a yield of 4.38%. Gilead Sciences’s dividend payout ratio (DPR) is presently 855.56%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Large investors have recently made changes to their positions in the company. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $210,000. Federated Hermes Inc. boosted its position in Gilead Sciences by 4.9% during the fourth quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock worth $306,814,000 after purchasing an additional 175,925 shares during the period. Charles Schwab Investment Management Inc. boosted its position in Gilead Sciences by 1.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock worth $589,873,000 after purchasing an additional 87,482 shares during the period. Wetzel Investment Advisors Inc. bought a new stake in Gilead Sciences during the fourth quarter worth approximately $74,000. Finally, Eagle Asset Management Inc. boosted its position in Gilead Sciences by 23.6% during the fourth quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock worth $25,724,000 after purchasing an additional 60,697 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.